Simcere Pharmaceutical Group Limited (2096.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Simcere Pharmaceutical Group Limited
Address
No. 699-18, Xuanwu Road
Nanjing, 210042
China
Phone
86 25 8556 6666
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6584
First IPO Date
October 27, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Yunshu Zhou | Chief Executive Officer | 0 | 1972 |
| Xi Wang | Vice President & Executive Director | 2.06M | 1983 |
| Yushan Wan | Chief Financial Officer, Joint Company Secretary & Executive Director | 6.98M | 1970 |
| Jinsheng Ren | Co-Founder & Chairman | 9.39M | 1962 |
| Renhong Tang | Executive Director | 11.04M | 1981 |
| Quanfu Feng | Vice President of Marketing | 0 | 1965 |
| Aik Han Goh | Senior Vice President & Chief Medical Officer | 0 | 1975 |
| Gaobo Zhou | Chief Investment Officer | 0 | 1979 |
| Tamas Oravecz | Senior Vice President & Chief Scientific Officer of Simcere Zaiming | 0 | N/A |
| Yongyu Wang | Senior Vice President & Chief Medical Officer of Simcere Zaiming | 0 | N/A |
Description
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
